|
|
 |
European Biopharmaceutical Review |
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique
position in scientific publishing. Published quarterly, it provides a dedicated platform
of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.
With editorial consisting of in-depth articles, case studies, meetings, and report
reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies.
Each quarterly edition examines topical areas of importance across the board of biopharmaceutical
research and development, with regular feature sections on BioBusiness
Development, Research and Innovation, BioDiscovery, BioManufacturing
plus special focuses on geographic or therapeutic territories.
Connect with us on Twitter: follow @EBRmagazine
|
|
 |
|
 |
|
|
 |
News and Press Releases |
 |
Lonza’s API Mid-Scale Manufacturing Facility Expansion in Nansha Enters Commercial Operation
Expanded capacity in Nansha, China, will support mid-scale
manufacturing to ensure a smooth transition between early-phase and
large-scale commercial production. Capabilities add to Lonza’s
integrated global manufacturing network, which maintains rigorous
quality and regulatory standards around the world
More info >> |
|
 |
White Papers |
 |
Overcoming research challenges with Adaptive Trials
PCI Pharma Services
There has been cause for concern within the pharmaceutical industry over
the last five years, regarding increasing research and development
costs, combined with a fall in the number of new drugs brought to
market. In an attempt to overcome this issue there has been a
significant rise in the use of adaptive clinical trial designs, whilst
saving time and money as well as facilitating more effective decision
making. One of the biggest challenges that pharmaceutical companies have
experienced has been delivering compliant clinical trials supplies
across diverse patient populations in the relatively short timeframes
that adaptive trial designs require, remaining focused on ensuring that
patient compliance and product quality is in no way compromised. This
demand has led to the launch of fast response services that support
Research and Development in responding to changing dosing regimens
mid-trial.
More info >> |
|
|